Literature DB >> 16980950

Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome.

Raymond Lai1, Shilo V Lefresne, Bevin Franko, David Hui, Imran Mirza, Adnan Mansoor, Hesham M Amin, Yupo Ma.   

Abstract

Mantle cell lymphoma is an aggressive B-cell lymphoma for which the biology is incompletely understood. Previous studies have reported that somatic hypermutation of the variable region of the immunoglobulin heavy chain gene (V(H)), as commonly defined as <98% homology, can be detected in approximately one-third of mantle cell lymphoma, although the V(H) mutation status has not been found to significantly correlate with patient survival. In this study, we assessed V(H) mutation in 55 mantle cell lymphomas using a method slightly different from those used in the previous studies, and we came to different conclusions. Using DNA extracted from formalin-fixed/paraffin-embedded tumors in all cases, we identified monoclonal IGH bands in 54 of 55 cases with the FR1c/J(H) primer; a monoclonal IGH band was amplified using another IGH primer set, FR256/J(H), in the remaining case. Cloning was performed in all cases, and an average of six clones were sequenced and analyzed for each case. Intraclonal heterogeneity was detected in 45 (82%) cases. Further analysis was performed in 53 cases, in which a predominant IGH species was identified. Most (32 of 53 cases, 60%) cases were 'mutated', with <98% homology. V(H)1-69, V(H)4-59 and V(H)3-74 were utilized in 29 (55%) cases. Intraclonal evolution and non-productive V(H) rearrangements were more frequent in the mutated group. Patients with the 'mutated' genotype had longer overall survival (P=0.017, Log rank) that is independent of the international prognostic index. To conclude, our data suggest that the V(H) mutation frequency in mantle cell lymphoma may be higher than previously believed. Importantly, using our methodology, we found that the V(H) mutation status may be a useful prognostic marker for these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980950     DOI: 10.1038/modpathol.3800677

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  9 in total

1.  Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Authors:  Katherine I Lin; Constantine S Tam; Michael J Keating; William G Wierda; Susan O'Brien; Susan Lerner; Kevin R Coombes; Ellen Schlette; Alessandra Ferrajoli; Lynn L Barron; Thomas J Kipps; Laura Rassenti; Stefan Faderl; Hagop Kantarjian; Lynne V Abruzzo
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

2.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

3.  Indolent mantle cell lymphoma.

Authors:  Michelle Furtado; Simon Rule
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

4.  Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.

Authors:  Fanny Baran-Marszak; Mohand Boukhiar; Stéphanie Harel; Christelle Laguillier; Claudine Roger; Remy Gressin; Antoine Martin; Remi Fagard; Nadine Varin-Blank; Florence Ajchenbaum-Cymbalista; Dominique Ledoux
Journal:  Haematologica       Date:  2010-07-27       Impact factor: 9.941

5.  Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion.

Authors:  Wenbin Xiao; Wayne W Chen; Lynn Sorbara; Theresa Davies-Hill; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Hum Pathol       Date:  2016-05-14       Impact factor: 3.466

6.  Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma.

Authors:  M Todorovic; M Pavlovic; B Balint; N Kraguljac; B Mihaljevic; A Bogdanovic; I Elezovic; D Boskovic; M Colovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.

Authors:  Teresa Sadras; Mickaël Martin; Kohei Kume; Mark E Robinson; Supraja Saravanakumar; Gal Lenz; Zhengshan Chen; Joo Y Song; Tanya Siddiqi; Laura Oksa; Anne Marie Knapp; Jevon Cutler; Kadriye Nehir Cosgun; Lars Klemm; Veronika Ecker; Janet Winchester; Dana Ghergus; Pauline Soulas-Sprauel; Friedemann Kiefer; Nora Heisterkamp; Akhilesh Pandey; Vu Ngo; Lili Wang; Hassan Jumaa; Maike Buchner; Jürgen Ruland; Wing-Chung Chan; Eric Meffre; Thierry Martin; Markus Müschen
Journal:  Mol Cell       Date:  2021-04-19       Impact factor: 17.970

Review 8.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

9.  Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series.

Authors:  Joaquim Carreras; Naoya Nakamura; Rifat Hamoudi
Journal:  Healthcare (Basel)       Date:  2022-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.